Compare NBTX & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBTX | INSP |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | France | United States |
| Employees | 97 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2018 | 2018 |
| Metric | NBTX | INSP |
|---|---|---|
| Price | $36.87 | $66.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 16 |
| Target Price | $36.00 | ★ $94.00 |
| AVG Volume (30 Days) | 155.1K | ★ 425.4K |
| Earning Date | 03-31-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | $58.17 | $8.02 |
| Revenue Next Year | N/A | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $9.32 | $38.91 |
| 52 Week High | $57.14 | $147.03 |
| Indicator | NBTX | INSP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.